Experts Make the Case for Buprenorphine Use in Cancer-Related Pain Management
June 28th 2022Mary Lynn McPherson, PharmD, BCPS, FAAHPM, and Amy A. Case, MD, FAAHPM, argue that buprenorphine should play a larger role in cancer-related pain management because of its unique pharmacology and consequent safety profile.
Oral Minoxidil Demonstrates Efficacy in Treating Later Stage Alopecia in Cancer Survivors
June 27th 2022Results of a single-center study presented at the 2022 ASCO Annual Meeting showed that oral minoxidil may be effective in treating late alopecia. Moving forward, these efforts in survivorship care will need to be expanded to less resourced areas, experts said.
FDA Follow-Up: Utilizing Relatlimab/Nivolumab in Clinical Practice for Metastatic Melanoma
March 25th 2022Oncology Nursing News® speaks with Hussein A. Tawbi, MD, PhD, principal investigator of the phase 2/3 RELATIVITY-046 trial, about the significance of the relatlimab/nivolumab approval for patients with unresectable or metastatic melanoma.
FDA Follow-Up: Utilizing Tebentafusp in Clinical Practice for Metastatic Uveal Melanoma
February 4th 2022Oncology Nursing News® meets with the lead investigator behind the phase 3 IMCgp100-202 trial to better understand the significance of tebentafusp’s approval and to determine what oncology nurses need to know about the new agent.
Pembrolizumab May Be Associated with Sustainable Relapse-Free Survival in High-Risk Melanoma
November 8th 2021After 6 months of additional follow-up, patients with resected high-risk stage II melanoma continued to experience improved relapse-free survival following treatment with adjuvant pembrolizumab.
Precision Medicine Highlights the Importance of Biomarkers in Melanoma
December 4th 2020With the identification of actionable alterations, precision medicine continues to lead the way in all areas of oncology, but especially in melanoma, according to Jason J. Luke, MD, FACP, who added that, in order to successfully apply personalized therapy, it’s critical to be fluent in the differences between biomarkers.